Results 11 to 20 of about 1,440 (183)
Early detection of transformation to BPDCN in a patient with MDS [PDF]
Experimental Hematology & Oncology, 2018 Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by neoplastic cells that are positive for CD123, CD4, BDCA2, and TCL1 and aberrant expression of CD56.
Kamal Chamoun +12 more
doaj +4 more sources
Metformin dual-targets metabolism and survival pathways in BPDCN. [PDF]
iScienceBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy with limited therapeutic options. Metformin, a commonly prescribed antidiabetic drug, has recently gained attention for its anticancer potential, but its effects on BPDCN remain unknown.
Mekkaoui Z +13 more
europepmc +4 more sources
t(8;14)(q24;q32) in BPDCN [PDF]
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2019 Review on t(8;14)(q24;q32) in BPDCN, with data on ...
Huret, Jean-Loup
openaire +4 more sources
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [PDF]
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018 Review on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), with data on clinics, and the genes involved.
Meloni-Ehrig, Aurelia
openaire +4 more sources
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) — diagnostic and therapeutic challenge [PDF]
Hematology in Clinical Practice, 2021 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive haematological malignancy. The disease usually affects the skin, bone marrow, peripheral blood and less commonly lymph nodes. The actual incidence of BPDCN is currently unknown.
Jarosław Wajs +4 more
openaire +2 more sources
Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review. [PDF]
Leukemia Research Reports, 2022 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare type of leukemia in children, Although BPDCN is a chemo-sensitive tumor, the relapse rate is very high.
Dima Abla +4 more
doaj +2 more sources
eJHaem, 2023 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is recurrently mutated in epigenetic pathway genes. We studied the myeloid‐related genetic mutations in a cohort of five patients with BPDCN and one paired relapse case at our institution and ...
Xi Zhang +3 more
doaj +2 more sources
Clinical Lymphoma Myeloma and Leukemia, 2023 Background BPDCN is a rare, clinically aggressive hematologic malignancy originating from the precursors of plasmacytoid dendritic cells. In 2008 it was recognized by WHO as a distinct entity.
Astghik Voskanyan +30 more
openaire +2 more sources
BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
eJHaem, 2021 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poor prognosis and no treatment consensus. Combining chemotherapy and immunotherapy is a promising strategy to enhance therapeutic effect. Before combining these
Margaux Poussard +16 more
doaj +2 more sources
Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) [PDF]
Bone Marrow Transplantation, 2021 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive hematological malignancy; however, some patients achieve durable remission with allogeneic hematopoietic cell transplantation (allo-HCT). We report on all 17 patients with BPDCN who underwent allo-HCT at our center between 2000 and 2020. The median age was 39 (18-67) years.
Qaiser Bashir +19 more
openaire +3 more sources